SOUTH SAN FRANCISCO, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback